Register for our free email digests:
Samsung Bioepis Co. Ltd.
Division of Samsung Electronics Co. Ltd.
www.samsungbioepis.com
Latest From Samsung Bioepis Co. Ltd.
Samsung Bioepis Targets Brazil With Brenzys
Samsung Bioepis has entered a fifth continent by launching its Brenzys etanercept biosimilar in Brazil, as part of global expansion plans for the business.
Biocon And Mylan Get CRL From FDA For Lantus Rival
Biocon has run into fresh trouble with the US Food and Drug Administration after receiving a complete response letter on its application for insulin glargine, a proposed rival to Sanofi’s top-selling Lantus biologic.
US Insurer United Rewards Amgen’s Early Entry With Bevacizumab And Trastuzumab
Amgen’s Mvasi and Kanjinti alternatives to Roche’s Avastin bevacizumab and Herceptin trastuzumab brands will from 1 October be preferred by plans administered by the largest US health insurer, UnitedHealthcare.
Advances On the Biosimilar Litigation Battlefield
A look at the evolution of litigation, from Amgen's 'bold' at-risk launch of Herceptin and Avastin biosimilars to the jump in settlements, new battles over manufacturing information and an expected petition to the Supreme Court.
Company Information
- Industry
-
Biotechnology
- Large Molecule
- Pharmaceuticals
- Therapeutic Areas
- Cancer
- Immune Disorders
- Metabolic Disorders
- Alias(es)
- Ownership
- Private
- Headquarters
-
Worldwide
-
Asia
-
Pacific Rim
-
South Korea
-
South Korea
-
Pacific Rim
-
Asia
- Parent & Subsidiaries
- Samsung Electronics Co. Ltd.
- Senior Management
- Christopher Hansung Ko, PhD, CEO
- Contact Info
-
Samsung Bioepis Co. Ltd.
Phone: 32 455 3114
107, Cheomdan-daero
Yeonsu-Gu
Incheon, 406-840
South Korea
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice